Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: Expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy

Cancer Immunology, Immunotherapy

Volumn 57, Issue 6, 2008, Pages 897-906

  Merrick, Alison ^a   Diaz, Rosa Maria ^b   O'Donnell, Dearbhaile ^c   Selby, Peter ^a   Vile, Richard ^b   Melcher, Alan ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b MAYO CLINIC   (United States)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

Cancer immunotherapy; Cancer vaccines; Dendritic cells; Tumour associated antigens

Indexed keywords

DENDRITIC CELL VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELAN A; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL ASSAY; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; DENDRITIC CELLS; FEMALE; HISTOCOMPATIBILITY ANTIGENS; IMMUNOTHERAPY; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PEPTIDES; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 43349105987     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0426-9     Document Type: Article

References (28)

1. Banchereau J et al (2005) Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J Immunother 28(5):505-516
2. Guermonprez P et al (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20:621-667
3. Rescigno M et al (1997) Dendritic cell maturation is required for initiation of the immune response. J Leukoc Biol 61(4):415-421
4. Smits HH et al (2005) Different faces of regulatory DCs in homeostasis and immunity. Trends Immunol 26(3):123-129
5. Ferlazzo G (2005) Natural killer and dendritic cell liaison: recent insights and open questions. Immunol Lett 101(1):12-17
6. Melcher A et al (2002) Dendritic cells for the immunotherapy of cancer. Clin Oncol (R Coll Radiol) 14(3):185-192
7. Gong J et al (1997) Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3(5):558-561
8. Phan V et al (2003) A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat Med 9(9):1215-1219
9. Plautz GE et al (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90(10):4645-4649
10. Errington F et al (2006) Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. Clin Cancer Res 12(4):1333-1341
11. Neves AR et al (2005) Dendritic cells derived from metastatic cancer patients vaccinated with allogeneic dendritic cell-autologous tumor cell hybrids express more CD86 and induce higher levels of interferon-gamma in mixed lymphocyte reactions. Cancer Immunol Immunother 54(1):61-66
12. Hus I et al (2005) Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 19(9):1621-1627
13. Holtl L et al (2005) Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 54(7):663-670
14. Gong J et al (2000) Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 165(3):1705-1711
15. Tanaka Y et al (2001) Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol 101(2):192-200
16. Siders WM et al (2003) Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 7(4):498-505
17. Suzuki T et al (2005) Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin Cancer Res 11(1):58-66
18. Wells JW et al (2007) Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity. Cancer Immunol Immunother 56(12):1861-1873
19. Tirapu I et al (2004) Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int J Cancer 110(1):51-60
20. Chakraborty NG et al (2004) Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol 65(8):794-802
21. Babatz J et al (2006) Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother 55(3):268-276
22. Wierecky J et al (2006) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66(11):5910-5918
23. Melcher A et al (1999) Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Cancer Res 59(12):2802-2805
24. Gallucci S, Lolkema M, Matzinger P (1999) Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5(11):1249-1255
25. Inaba K et al (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176(6):1693-1702
26. Petersen MS et al (2000) Strain-specific variations in the development of dendritic cells in murine bone-marrow cultures. Scand J Immunol 51(6):586-594
27. Gallucci S, Matzinger P (2001) Danger signals: SOS to the immune system. Curr Opin Immunol 13(1):114-119
28. Yasuda T et al (2007) Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol Immunother 56(7):1025-1036